STAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatment

STAT PlusBreaking News FDA approves new pancreatic cancer drug expected to usher in new era of treatment The therapy, Rasonque from Revolution Medicines, nearly doubled overall survival in a clinical trial Manage alerts for this article Email this article Share this article By Adam Feuerstein and Angus ChenAug. 26, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

You can reach Adam on Signal at stataf.54.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. The Food and Drug Administration on Wednesday approved a life-extending treatment for advanced pancreatic cancer — a medicine made by the biotech company Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy.

The drug, called daraxonrasib, will be sold under the brand name Rasonque. The FDA’s approval was supported by a practice-changing clinical trial that read out earlier this year. Patients with advanced pancreatic cancer who received Rasonque as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.

Advertisement “It will be transformative in the way we treat pancreas cancer. It’s the biggest development we’ve had in pancreas cancer in decades,” said Andrew Ko, a medical oncologist specializing in gastrointestinal cancers at the University of California, San Francisco. “I’m so thankful for this as an advance for our patients.” STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Cancer, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.

He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community.

You can reach Angus on Signal at angus.08. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout August 26, 2026 STAT Plus: Key data on a new class of cardio drugs are coming AI Prognosis August 26, 2026 STAT Plus: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials Advertisement Biotech August 25, 2026 STAT Plus: After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026 The Readout August 24, 2026 STAT Plus: Lady Gaga and her fiancé launch a biotech startup Biotech August 24, 2026 STAT Plus: FDA pauses Regenxbio gene therapy trial again due to safety concerns Subscriber Picks